Scholarlink

<p>A defining characteristic of the Antibiotic Resistance crisis is the lack of substantial investment by the biopharmaceutical industry, which sees limited profit potential in novel antibiotics. We argue for redefining the salient problem for novel antibiotic development as the high rates of empiric treatment failure versus focusing only on infection deaths caused by a few specific, highly drug-resistant pathogens. In turn, we propose a novel framework for the antibiotic discovery community: focus on developing pathogen-general potentiators, which could solve the problem of empiric treatment failure and have the profit potential necessary to attract industry investment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Rethinking the unmet need for novel antibiotics

  • 期刊论文

  • 发表日期：

    2026年1月6日

查看全文
  • Eric J. Evans,
  • P. Douglas Witt,
  • George G. Zhanel,
  • David J. Klein

摘要

A defining characteristic of the Antibiotic Resistance crisis is the lack of substantial investment by the biopharmaceutical industry, which sees limited profit potential in novel antibiotics. We argue for redefining the salient problem for novel antibiotic development as the high rates of empiric treatment failure versus focusing only on infection deaths caused by a few specific, highly drug-resistant pathogens. In turn, we propose a novel framework for the antibiotic discovery community: focus on developing pathogen-general potentiators, which could solve the problem of empiric treatment failure and have the profit potential necessary to attract industry investment.